OPKO Health, Inc. Convertible Notes Payable, Current
OPKO Health, Inc. (OPK) had Convertible Notes Payable, Current of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt and Lease Obligation, Current › Long-Term Debt, Current Maturities › Notes and Loans Payable, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2026-02-26
- 2025-12-31: Convertible Notes Payable, Current $0.00.
- 2025-09-30: Convertible Notes Payable, Current $0.00.
- 2025-06-30: Convertible Notes Payable, Current $0.00.
- 2025-03-31: Convertible Notes Payable, Current $101.24M.
| Period end | Convertible Notes Payable, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-29 |
| 2025-06-30 | $0.00 10-Q · filed 2025-07-31 |
| 2025-03-31 | $101.24M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $170.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $170.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $170.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $170.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-06 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 |
| 2022-12-31 | $3.05M 10-K · filed 2024-03-01 |
| 2022-09-30 | $70.63M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-08 |
| 2018-12-31 | $31.56M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |